Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sandoz Group AGXSWX:SDZ -2.68%11 Equity-to-Asset is 0.43 as of Dec. 2025, which is 2% below its 10-year median of 0.44. GuruFocus rates XSWX:SDZ with a GF Score™ of 11/100. The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Sandoz Group AG ranks worse than 72.42% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Sandoz Group AG's Total Stockholders Equity for the quarter that ended in Dec. 2025 was CHF7,478 Mil. Sandoz Group AG's Total Assets for the quarter that ended in Dec. 2025 was CHF17,557 Mil.
Therefore, Sandoz Group AG's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.43.
The historical rank and industry rank for Sandoz Group AG's Equity-to-Asset or its related term are showing as below:
XSWX:SDZ'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.41 Med: 0.44 Max: 0.5
Current: 0.43
During the past 4 years, the highest Equity to Asset Ratio of Sandoz Group AG was 0.50. The lowest was 0.41. And the median was 0.44.
XSWX:SDZ's Equity-to-Asset is ranked worse than 72.42% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs XSWX:SDZ: 0.43
Sandoz Group AG (XSWX:SDZ) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Sandoz Group AG Equity-to-Asset Related Terms
Sandoz Group AG Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Sandoz Group AG's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:SDZ vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sandoz Group AG Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Sandoz Group AG's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Sandoz Group AG's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sandoz Group AG (XSWX:SDZ) has a Equity-to-Asset of 0.43 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sandoz Group AG and its competitors. This is near median its historical median of 0.44. Over the past decade, Sandoz Group AG's Equity-to-Asset has ranged from 0.41 to 0.50. According to the industry distribution chart, Sandoz Group AG ranks #730 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 72.4%.
Is Sandoz Group AG's Equity-to-Asset too high?
Sandoz Group AG's current Equity-to-Asset of 0.43 is near median its 10-year median of 0.44. Over the past 10 years, this metric has ranged from a low of 0.41 to a high of 0.50. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Sandoz Group AG's value of 0.43 is 29.5% below this industry median. Based on the distribution chart, Sandoz Group AG ranks #730 out of 1008 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Sandoz Group AG has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sandoz Group AG ranks #730 out of 1008 companies for Equity-to-Asset. This places Sandoz Group AG in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Sandoz Group AG's value of 0.43 is 29.5% below this benchmark. Historically, Sandoz Group AG's own Equity-to-Asset has ranged from 0.41 to 0.50 over the past decade. While the company's 10-year median is 0.44 vs. the industry median of 0.61, Sandoz Group AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sandoz Group AG's current Equity-to-Asset of 0.43 is 29.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Sandoz Group AG and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sandoz Group AG's current Equity-to-Asset is 0.43, which is near median its own 10-year median of 0.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Sandoz Group AG (XSWX:SDZ) has a current Equity-to-Asset of 0.43. The current Equity-to-Asset is 0.43, which is near median its 10-year median of 0.44 and 29.5% below the Drug Manufacturers industry median of 0.61. Sandoz Group AG's overall GF Score™ is 11/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Sandoz Group AG (XSWX:SDZ), the current Equity-to-Asset is 0.43 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
11GF Score
Get the complete analysis for XSWX:SDZ
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:SDZ has been successfully added to your 
